You are here:
glucosamine sulphate (Glusartel)
Advice
following a resubmission:
glucosamine sulphate (Glusartel®) is not recommended for use within NHS Scotland.
Indication under review: relief of symptoms in mild to moderate osteoarthritis of the knee.
In a placebo- and active-comparator study, glucosamine sulphate 1,500mg once daily was significantly better than placebo in the treatment of symptoms associated with osteoarthritis of the knee.
Overall the submitting company did not present a sufficiently robust clinical and economic analysis to gain acceptance by SMC.
Drug Details
| Drug Name: | glucosamine sulphate (Glusartel) |
|---|---|
| SMC Drug ID: | 647/10 |
| Manufacturer: | HFA Healthcare Ltd |
| Indication: | For the relief of symptoms in mild to moderate osteoarthritis of the knee. |
| BNF Category: | |
| Sub Category: | 10.1 Drugs used in rheumatic diseases and gout |
| Submission Type: | Resubmission |
| Status: | Not Recommended |
| Date Advice Published: | 8 August 2011 |
Archived Advice
| glucosamine sulphate sodium chloride (Glusartel) | Full submission | 8 November 2010 |